07.05.24 -- Biopharma Outsourcing Analogs: From Cars To Eggs

Not really into choosing extended time away and exhibit halls over the simple pleasures of summertime? No reason to put your CDMO search on hold – Outsourced Pharma Capacity Update’s PARTNER WEEK is here! Take the travel and headache out of your plans and join us right from your computer. Assess potential fit for your next drug development project in convenient 20-minute segments – all grouped by molecule type. Presenters will share current available capacity across featured capabilities. Register for free.

Startups and Big Pharma companies alike are considering India as an alternative to working with China. Is it safe to do business with India? Let's do a deep dive, with insights from American and Indian attorneys.

Benjamin Stevens, Director CMC Policy and Advocacy at GSK provides some initial thoughts on the regulatory aspects related to moving programs to and through the clinic as quickly as possible.

HPAPIs offer benefits including reduced side effects and high specificity for patients. However, to ensure safety to personnel throughout production, manufacturers must effectively utilize containment and well-designed equipment.

Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.

Examine a new methodology that holds significant promise for identifying APIs at risk for NDSRI formation, enabling manufacturers to ensure compliance.

The dynamic pharmaceutical landscape demands agility and strategic foresight. Explore how leveraging a key partnership helped to overcome a looming patent expiry for a second-generation acne medication.

Review the case study and learn how KinetiSol Solid Dispersion lowered patients' pill burdens and demonstrated an improved therapeutic response for Galeterone.

Our combined method development experience ensures that client methods are robust, effective, flexible, innovative and allow true stability indication.

We can support discovery, preclinical, clinical and commercial programs for New Chemical Entities (NCEs). Review our network's medicinal chemistry capabilities and contact us to simplify your outsourcing solutions.

Nanoform’s award-winning Controlled Expansion of Supercritical Solutions (CESS®) technology is a bottom-up nanoparticle engineering approach that enables the creation of API nanoparticles and can unlock the full therapeutic potential of small molecule drugs.